Amelioration of lactic acid sensations in sensitive skin by stimulating the barrier function and improving the ceramide profile
We determined whether compensating ceramides in the stratum corneum (SC) may ameliorate the impaired barrier function and subsequently attenuate the enhanced skin sensitivity. Treatment for 4 weeks with the ceramide complex cream or the placebo cream significantly ameliorated the intensity of lactic acid sensations in 39 female subjects with sensitive skin, the degree of which was attenuated to a greater extent at 1 week by the ceramide complex cream compared with the placebo cream. The amelioration of skin sensations was accompanied by a significant increase in total ceramide content in the SC elicited by the ceramide complex cream that was significantly more effective than the placebo cream at 4 weeks. Consistently, TEWL and conductance values were significantly decreased or increased at 1 and 4 weeks, respectively, to a greater extent by the ceramide complex cream than by the placebo cream. TEWL levels were significantly correlated with the increased levels of SC total ceramide in the ceramide complex cream-treated skin but not in the placebo cream-treated skin. Thus, the amelioration of lactic acid sensations by topical application of a ceramide complex cream, provides a deep insight into the pathophysiology of sensitive skin as a reduced barrier function-dependent sub-clinical sensory response.
KeywordsSensitive skin Barrier function Ceramide Stinging test
Liquid chromatography/mass spectrometry
Trans-epidermal water loss
We thank Drs A. Naoe and H. Tsujimura (Kao Corporation, Japan) for lipid analysis.
Compliance with ethical standards
Conflict of interest
The authors state no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
- 1.Arikawa J, Ishibashi M, Kawashima M, Takagi Y, Ichikawa Y, Imokawa G (2002) Decreased levels of sphingosine, a natural anti-microbial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by Staphylococcus aureus. J Invest Dermatol 119(2):433–439CrossRefPubMedGoogle Scholar
- 2.De Lacharrière O (2002) Peaux sensibles, peaux réactives. Cosmétologie et Dermatologie Esthétique 50-220-A-10Google Scholar
- 6.Forsch PJ, Kligman AM (1977) A method for appraising the stinging capacity of topically applied substances. J Soc Cosmet Chem 28(5):197–209Google Scholar
- 7.Funasaka Y, Bito T, Yamamoto M, Nishigori C, Ishihashi M, Nakamura T, Ishida K, Sato H, Imokawa G (2004) Clinical evaluation of “Curel UV Milk” and “Curel UV Cream” in subjects with low barrier function’s skin. Skin Res 31(1):62–74Google Scholar
- 12.Holleran WM, Ginns EI, Menon GK, Grundmann JU, Fartasch M, McKinney CE, Elias PM, Sidransky E (1994) Consequences of beta-glucocerebrosidase deficiency in epidermis. ultrastructure and permeability barrier alterations in Gaucher disease. J Clin Invest 93(4):1756–1764CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Imokawa G (1999) Skin moisturizers: development and clinical use ceramides. In: Loden M (ed) Dry skin and moisturizers. CRC Press, pp 269–299Google Scholar
- 15.Imokawa G (2001) Ceramides as natural moisturizing factors and their efficacy in dry skin. In: Leyden JJ, Rawlings AV (eds) Skin moisturization. Marcel Dekker Inc., pp 267–302Google Scholar
- 18.Imokawa G, Yada Y, Higuchi K, Okuda M, Ohashi Y, Kawamata A (1994) Pseudo-acylceramide with linoleic acid produces selective recovery of diminished cutaneous barrier function in essential fatty acid deficient rats and has anvinhibitory effect on epidermal hyperplasia. J Clin Invest 94(1):89–96CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Ishibashi M, Arikawa J, Okamoto R, Kawashima M, Takagi Y, Oguchi K, Imokawa G (2003) The abnormal expression of the novel epidermal enzyme, glucosylceramide deacylase and the accumulation of its enzymatic reaction product, glucosylsphingosine in the skin of patients with atopic dermatitis. Lab Invest 88(3):397–408CrossRefGoogle Scholar
- 23.Janssens M, van Smeden J, Gooris GS, Bras W, Portale G, Caspers PJ, Vreeken RJ, Hankemeier T, Kezic S, Wolterbeek R, Lavrijsen AP, Bouwstra JA (2012) Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients. J Lipid Res 53(10):2755–2766CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Matsuki H (2006) Significance of barrier repair in non-lesinal dry skin of atopic dermatitis: Efficacy of a topically applied ceramide cream. Nishihihon J Dermatol 64:606–611Google Scholar
- 36.Nakajima K, Terao M, Takaishi M, Kataoka S, Goto-Inoue N, Setou M, Horie K, Sakamoto F, Ito M, Azukizawa H, Kitaba S, Murota H, Itami S, Katayama I, Takeda J, Sano S (2013) Barrier abnormality due to ceramide deficiency leads to psoriasiform inflammation in a mouse model. J Invest Dermatol 133(11):2555–2565CrossRefPubMedGoogle Scholar
- 37.Nakamura T, Satoh H, Imokawa G, Miyachi Y (2000) Clinical test of skin care products on atopic dry skin. Skin Res 42(2):264–269Google Scholar
- 38.Ohta M, Hikima R, Ogawa T (2000) Physiological characteristics of sensitive skin classified by stinging test. J Cosmet Sci Soc Jpn 24(3):163–167Google Scholar
- 40.Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O’Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH (2006) Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 38(4):441–446CrossRefPubMedGoogle Scholar
- 42.Sandilands A, O’Regan GM, Liao H, Zhao Y, Terron-Kwiatkowski A, Watson RM, Cassidy AJ, Goudie DR, Smith FJ, McLean WH, Irvine AD (2006) Prevalent and rare mutations in the gene encoding filaggrin cause ichthyosis vulgaris and predispose individuals to atopic dermatitis. J Invest Dermatol 126(8):1770–1775CrossRefPubMedGoogle Scholar
- 49.van Drongelen V, Alloul-Ramdhani M, Danso MO, Mieremet A, Mulder A, van Smeden J, Bouwstra JA, El Ghalbzouri A (2013) Knock-down of filaggrin does not affect lipid organization and composition in stratum corneum of reconstructed human skin equivalents. Exp Dermatol 22(12):807–812CrossRefPubMedGoogle Scholar
- 51.Yokota T, Matsumoto M, Sakamati T (2003) Classification of sensitive skin and development of a treatment system appropriate for each group. IFSCC Mag 6(4):303–307Google Scholar
- 52.Yamanaka M, Tshibashi O, Takahashi A, Sato H, Imokawa G (2001) Clinical evaluation of Curel medicated cream in patients with atopic dermatitis. Skin Res 43(4–5):278–285Google Scholar